Jaume Pons - Jun 4, 2024 Form 4 Insider Report for ALX ONCOLOGY HOLDINGS INC (ALXO)

Signature
/s/ Peter Garcia, by power of attorney
Stock symbol
ALXO
Transactions as of
Jun 4, 2024
Transactions value $
-$148,852
Form type
4
Date filed
6/6/2024, 04:06 PM
Previous filing
May 8, 2024
Next filing
Jul 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALXO Common Stock Options Exercise $19.8K +20K +3.31% $0.99* 624K Jun 4, 2024 Direct
transaction ALXO Common Stock Sale -$169K -20K -3.2% $8.43 604K Jun 4, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALXO Employee Stock Option (right to buy) Options Exercise $0 -20K -10.84% $0.00 164K Jun 4, 2024 Common Stock 20K $0.99 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.17 to $8.87, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3 The shares subject to the option are fully vested and immediately exercisable.